BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaźmierczak A, Czapski GA, Adamczyk A, Gajkowska B, Strosznajder JB. A novel mechanism of non-Aβ component of Alzheimer's disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5). Neurochem Int 2011;58:206-14. [PMID: 21130128 DOI: 10.1016/j.neuint.2010.11.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Kawahara M, Kato-Negishi M, Tanaka KI. Neurometals in the Pathogenesis of Prion Diseases. Int J Mol Sci 2021;22:1267. [PMID: 33525334 DOI: 10.3390/ijms22031267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Da Pozzo E, La Pietra V, Cosimelli B, Da Settimo F, Giacomelli C, Marinelli L, Martini C, Novellino E, Taliani S, Greco G. p53 functional inhibitors behaving like pifithrin-β counteract the Alzheimer peptide non-β-amyloid component effects in human SH-SY5Y cells. ACS Chem Neurosci 2014;5:390-9. [PMID: 24646317 DOI: 10.1021/cn4002208] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
3 Wilkaniec A, Czapski GA, Adamczyk A. Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses. J Neurochem 2016;136:222-33. [PMID: 26376455 DOI: 10.1111/jnc.13365] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
4 Eugene C, Laghaei R, Mousseau N. Early oligomerization stages for the non-amyloid component of α-synuclein amyloid. The Journal of Chemical Physics 2014;141:135103. [DOI: 10.1063/1.4896381] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
5 Wilkaniec A, Gąssowska-Dobrowolska M, Strawski M, Adamczyk A, Czapski GA. Inhibition of cyclin-dependent kinase 5 affects early neuroinflammatory signalling in murine model of amyloid beta toxicity. J Neuroinflammation 2018;15:1. [PMID: 29301548 DOI: 10.1186/s12974-017-1027-y] [Cited by in Crossref: 47] [Cited by in F6Publishing: 25] [Article Influence: 15.7] [Reference Citation Analysis]
6 Dominiak A, Wilkaniec A, Wroczyński P, Adamczyk A. Selenium in the Therapy of Neurological Diseases. Where is it Going? Curr Neuropharmacol 2016;14:282-99. [PMID: 26549649 DOI: 10.2174/1570159x14666151223100011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 6.8] [Reference Citation Analysis]
7 Cieślik M, Czapski GA, Strosznajder JB. The Molecular Mechanism of Amyloid β42 Peptide Toxicity: The Role of Sphingosine Kinase-1 and Mitochondrial Sirtuins. PLoS One 2015;10:e0137193. [PMID: 26334640 DOI: 10.1371/journal.pone.0137193] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
8 Longhena F, Faustini G, Varanita T, Zaltieri M, Porrini V, Tessari I, Poliani PL, Missale C, Borroni B, Padovani A, Bubacco L, Pizzi M, Spano P, Bellucci A. Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains. Brain Pathol 2018;28:875-88. [PMID: 29330884 DOI: 10.1111/bpa.12587] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
9 Diaz-Moralli S, Tarrado-Castellarnau M, Miranda A, Cascante M. Targeting cell cycle regulation in cancer therapy. Pharmacol Ther. 2013;138:255-271. [PMID: 23356980 DOI: 10.1016/j.pharmthera.2013.01.011] [Cited by in Crossref: 185] [Cited by in F6Publishing: 182] [Article Influence: 23.1] [Reference Citation Analysis]
10 Kelly J, Moyeed R, Carroll C, Luo S, Li X. Genetic networks in Parkinson's and Alzheimer's disease. Aging (Albany NY) 2020;12:5221-43. [PMID: 32205467 DOI: 10.18632/aging.102943] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
11 Wilkaniec A, Strosznajder JB, Adamczyk A. Toxicity of extracellular secreted alpha-synuclein: Its role in nitrosative stress and neurodegeneration. Neurochem Int 2013;62:776-83. [PMID: 23416621 DOI: 10.1016/j.neuint.2013.02.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
12 Kelly J, Moyeed R, Carroll C, Albani D, Li X. Gene expression meta-analysis of Parkinson's disease and its relationship with Alzheimer's disease. Mol Brain 2019;12:16. [PMID: 30819229 DOI: 10.1186/s13041-019-0436-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 14.0] [Reference Citation Analysis]
13 Lam E, Choi SH, Pareek TK, Kim BG, Letterio JJ. Cyclin-dependent kinase 5 represses Foxp3 gene expression and Treg development through specific phosphorylation of Stat3 at Serine 727. Mol Immunol 2015;67:317-24. [PMID: 26198700 DOI: 10.1016/j.molimm.2015.06.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
14 Czapski GA, Gąssowska M, Wilkaniec A, Cieślik M, Adamczyk A. Extracellular alpha-synuclein induces calpain-dependent overactivation of cyclin-dependent kinase 5 in vitro. FEBS Lett 2013;587:3135-41. [PMID: 23954626 DOI: 10.1016/j.febslet.2013.07.053] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]